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Background:Oral biotin supplementation is known to interfere with biotin-streptavidin–based immunoassays,
including Roche's fifth-generation cardiac troponin T (cTnT) assay, which plays a critical role in the diagnosis of
myocardial infarction (MI). The utility of dilution, a quick and easymethod to detect and remove interferences, has
not been published for biotin interference.
Methods: Concentrations of cTnT were measured in pooled serum from clinical samples. Serum samples were
supplemented with biotin to known concentrations, then cTnT concentrations were remeasured to assess for
biotin interference. Samples were then diluted to assess for effective removal of biotin interference.
Results: At cTnT values near the critical reporting range for our institution (100 ng/L) we observed significant inter-
ference in measured values with added biotin concentrations above 50 ng/mL. In specimens without added biotin,
autodilution at a 1:10 ratio yielded a mean 157% capture of measured cTnT, precluding the use of autodilution for
detecting and mitigating biotin interference. A 1:10 dilution with serum containing 20–30 ng/L cTnT yielded a mean
capture of 107%, which was suitable for detecting underlying biotin interference in supplemented samples.
Conclusions: Biotin interference, at supraphysiologic concentrations, may create an artifactual reduction in
measured cTnT to levels that could lead to delayed detection of an MI. Dilution with serum of known cTnT
concentration of 20–30 ng/L is a fast and effective method to mitigate the analytical consequences of biotin
interference.
IMPACT STATEMENT
Quantitative measurements of serum cardiac biomarkers are critical components in the timely
diagnosis and management of suspected myocardial infarction (MI). The fifth-generation cTnT test
provides an opportunity for earlier and more sensitive detection of MI events. Oral biotin supple-
mentation can interfere with the test in a manner that may lead to missed or delayed MI diagnosis
and subsequent patient morbidity. Here we demonstrate the efficacy of a simple method (dilution
with serum with 20–30 ng/L cTnT) to detect and mitigate the effect of biotin interference.
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Biotin is a water-soluble B vitamin that acts as a
cofactor for multiple carboxylation reactions. Bio-
tin supplementation at 2.5–10mg/day is becoming
increasingly popular in the US for cosmetic and
medicinal uses despite limited efficacy data and
the rarity of dietary deficiency (1). Additionally,
high-dose biotin therapy (300 mg/day) is currently
under investigation for treatment of secondary
progressive multiple sclerosis, and some neurolo-
gists are prescribing high-dose biotin in anticipa-
tion of US Food and Drug Administration (FDA)2
approval (2).
Biotin binding to streptavidin is a key compo-
nent in many clinically used immunoassays (3).
Oral biotin supplementation at both low and high
dosages has been reported to interfere with many
tests, resulting in significant morbidity (4–7). In
November 2017, the FDA released a safety warn-
ing for biotin interference in laboratory testing (8). A
method of using streptavidin-coated beads to re-
move biotin interference has been reported (9, 10).
However, no studies of dilution, a potentially quicker
and easier approach to mitigate the effects of bio-
tin interference, have been published to date (11).
Currently, UC San Diego Health System uses the
fifth-generation cardiac troponin (cTnT) test to aid
in the diagnosis of acutemyocardial infarction (MI).
Neither allowing for natural clearance of biotin nor
manually removing biotin interference with
streptavidin-coated beads is a feasible method of
mitigating the effect of biotin interference owing to
the time-sensitive setting of MI diagnosis. Thus,
we sought to characterize the extent of biotin
interference in the cTnT test and the utility of
dilution for detecting and effectively mitigating
the clinical effect of biotin interference.
MATERIALS AND METHODS
Pooled serum from routine patient care was
collectedwithanapproved institutional reviewboard
protocol for existing tissue. Quantitative measure-
ments of cTnT were performed as singleton
measurements using the Troponin T Gen 5 STAT kit
on theRocheCobas8000e602 (Cat. 07398000160).
The data shown in Figs. 1 and 2 represent the aver-
age recovery (±SD) from singleton measurements
on 9 different patient specimens. Autodilution tests
were performed with the system's “autodilution”
function with the specified dilution ratio indicated.
Dilution with serumwasmanually performed. Calcu-
lation of cTnT concentration in the test solution was
derived with the formula Ctest = (Cresulted × Vresulted −
Cdiluent × Vdiluent) / Vtest, in which Ctest and Vtest are the
cTnT concentration and volume of the serum of in-
terest, respectively, Cresulted andVresulted are the cTnT
concentration resulted by analysis and total volume,
respectively, andCdiluent andVdiluent are thecTnTcon-
centration (previously measured) and volume of se-
rum used to dilute the interferent, respectively.
Biotin (Thermo Scientific, Cat. No. 29120, Lot No.
SG251613; purity, 99.5%) was reconstituted into a
0.1 g/L stock solution in distilled water and stored
at 4 °C. Biotin stock was diluted with 18.2 MΩ-cm
water (Siemens PureLab Ultra) into working solu-
tions that were then added into serum samples to
achieve the indicated final concentration of biotin.
All samples were supplemented with biotin solu-
tion or distilled water at 10% of the total volume of
the sample.
Statistical analysis was performed using Microsoft
Excel and Prism 8. Tukey's multiple comparison test
was performed for all group comparisons.
RESULTS
To characterize the effect of biotin supplemen-
tation and autodilution onmeasured cTnT concen-
trations, we tested patient samples with known
cTnT concentrations. We observed a mean cap-
ture of measured cTnT of 96%, 90%, 56%, and 11%
at biotin concentrations of 25, 50, 125, and 250
ng/mL, respectively (Fig. 1).
We next sought to characterize the dilution
characteristics of the assay at cTnT concentra-
tions of approximately 100 ng/L cTnT, using the
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autodilution feature available on the COBAS sys-
tem. We observed a mean capture of measured
cTnT of 113%, 133%, and 157% after autodilution
at 1:2, 1:5, and 1:10 ratios, respectively (Fig. 1). The
values for all samples are available in the “Autodi-
lution” column in Table 1 in the Data Supplement
that accompanies the online version of this article
at http://www.jalm.org/content/vol4/issue3. We
also showed significant increases in captured
value of similar magnitude when manually diluting
samples with Roche diluent solution M or patient
serumwithmeasured cTnT values below the lower
limit of quantification of 6 ng/L (see Fig. 1 in the
online Data Supplement). The increase in mea-
sured troponin concentration with autodilution,
manual dilution with the Roche diluent, or dilution
with a serum specimen containing cTnT <6 ng/L
would make it challenging to correct for biotin
interference.
In an effort to find a diluent with approximately
linear characteristics, we used patient serum with
measured cTnT between 20 and 30 ng/L. Using a
specimen with measured cTnT in this range, we
observed a mean recovery of measured cTnT of
104%, 105%, and 107% after dilution at 1:2, 1:5,
and 1:10 ratios, respectively (Fig. 2). Using this
diluent at a 1:10 dilution ratio, we observed a
mean recovery of cTnT of 107%, 100%, 104%,
95%, and 79% in the presence of 0, 25, 50, 125,
and 250 ng/L of biotin, respectively (Fig. 2). The
values for all samples are available in the “Dilu-
tion with serum containing approximately 20
ng/L cTnT” column in Table 1 in the online Data
Supplement.
0%
20%
40%
60%
80%
100%
120%
140%
160%
180%
0 25 50 125 250
Diluon of bion interference with autodiluon method
N = 9, Mean TnT, 87ng/L
Undiluted Autodilute1:2 Autodilute 1:5 Autodilute 1:10
 
Pe
rc
en
ta
ge
 o
f u
nd
ilu
te
d/
un
su
pp
le
m
en
te
d 
Tn
T 
va
lu
e
Added bion (ng/mL)
Fig. 1. Vertical axis displays percentage value of unsupplemented cTnT (serum supplemented with
water only is 100%).
Horizontal axis displays added biotin concentration (ng/mL). Values displayed represent mean ± 1 SD of 9 independent
results. Means with and without dilution at any ratio are all significantly different (adjusted P < 0.01, values not
shown).
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DISCUSSION
Biotin interference has been shown to cause
false-negative results for fifth-generation cTnT as-
says because the assay uses biotin-streptavidin
binding (12). In our hands, we see interference of
cTnT at biotin concentrations >50 ng/mL that may
be clinically significant. Pharmacokinetic studies
suggest that serum biotin concentrations >50
ng/mL could be sustained for 2–3 h after low-dose
(20 mg) biotin ingestion or up to 24 h after a single
high-dose (300 mg) biotin ingestion (13, 14). Thus,
despite relatively rapid clearance, biotin may lead
to clinically significant interference, especially in in-
stitutions practicing a variant of the 0-h/1-h tro-
ponin testing algorithm (15). Prevalence estimates
of analytically significant concentrations of biotin in
blood among patients differ between sources (16,
17). However, because of the high risk of patient
morbidity and mortality in such a scenario, clinical
laboratories using biotin-streptavidin–based plat-
forms should have a high level of suspicion for
biotin interference and implement an effective
evidence-based strategy to mitigate the potential
risk.
Manufacturer guidelines suggest that patients
ingesting oral biotin supplementation should wait
for natural clearance of biotin before undergoing
testing. However, the need for an expedient MI
diagnosis necessitates the use of a faster method
than natural clearance to obtain cardiac marker
testing results. The 510k submission for the Roche
5th generation cTnT assay indicates that the test
results did not deviate from linearity by more than
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Fig. 2. Vertical axis displays percentage value of unsupplemented cTnT (serum supplemented with
water only is 100%).
Horizontal axis displays added biotin concentration (ng/mL). Values displayed represent mean ± 1 SD of 9 independent
results. Means with and without dilution are significantly different in the presence of added biotin at 50 ng/mL or more
(adjusted P < 0.01, values not shown).
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12.4% over the range of 3–10000 ng/L (18). It
should be noted that the linearity studies de-
scribed in the package insert were performed “by
diluting one high analyte plasma sample (spiked
with recombinant cTnT) with native low analyte
plasma.” This process is consistent with the proto-
col we describe here. Unfortunately, our data and
that published by other groups (19) indicate that
the autodilution function of the COBAS platform
would not be ideal for detecting an underlying in-
terferent (e.g., biotin) because of the nonlinear di-
lution characteristics of the test for cTnT values
<100 ng/L with the Roche diluent. In a patient with
suspected biotin interference, it would be difficult
to determine if an increase in measured troponin
concentration after dilution (e.g., 18 ng/L cTnT
result predilution becoming 28 ng/L cTnT
after a 1:10 dilution is performed) is due to nonlin-
ear dilution effects or diluting out an underlying
interferent.
Using autodilution to uncover biotin interfer-
ence would potentiate false-positive assessments
of interference. As an example scenario: if a pa-
tient presents with a 0-h cTnT value of 60 ng/L and
the clinician suspects that biotin is interfering with
the assay, a 1:10 autodilution of the sample would
be predicted to yield approximately 95 ng/L even
in the absence of biotin interference. If this same
sample is diluted at a 1:10 ratio with serum at a
concentration of 20–30 ng/L cTnT, then a result of
60 ng/L (±10 ng/L) would result, indicating that sig-
nificant biotin interference is unlikely. If the sample
does indeed contain biotin at significant concen-
trations, then the results after dilution with serum
of 20–30 ng/L would increase in proportion to the
extent of biotin interference, indicating the pres-
ence of an underlying interferent.
The etiology of the observed nonlinearity of
dilution and the mechanism by which our pro-
posed method works are not clear. Data gener-
ated in our laboratory suggest that the increased
measured concentration of troponin observed
with autodilution, manual dilution using the
Roche diluent, or dilution with a specimen con-
taining <6 ng/L troponin is consistently about
4–5 ng/L cTnT above the expected value before
correcting for dilution factors throughout the
range of 7–90 ng/L of cTnT (see Fig. 2 in the
online Data Supplement). Our conjecture is that
dissociation of troponin complexes may acceler-
ate with dilution, leading to increased cTnT; how-
ever, additional research will be needed to
understand the molecular dynamics underlying
the observed phenomena.
Integration of the described dilution method
into institutional protocols will be a unique process
at each institution owing to the heterogeneity
of clinical and laboratory usages for the fifth-
generation cTnT assay. Serum with known cTnT
values is not a commonly stocked reagent in most
clinical laboratories. Given the importance of the
cTnT assay it may be necessary for laboratories to
generate andmaintain stocks of patient serum ex-
pressly for the purpose of dilution. Establishing a
protocol will require (a) clinicians to communicate
suspected biotin interference to the laboratory, (b)
for the laboratory to have a supply of serum with
known cTnT value to use as a diluent, (c) validate
the process for all relevant predilution cTnT values
as needed for the institution's clinical cTnT testing
protocols. These steps will require institution-
specific protocol development, validation, and
implementation.
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